On May 13, 2024 Aktis Oncology, a biotechnology company discovering and developing novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, reported an oral presentation at the Oligonucleotide & Peptide Therapeutics (TIDES USA) Conference 2024, being held May 14-17, 2024, in Boston, Mass. and virtually (Press release, Aktis Oncology, MAY 13, 2024, View Source;peptide-therapeutics-tides-usa-conference-2024-302143244.html [SID1234643174]). Presentation details can be found below and additional general conference information can be found on the TIDES website here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Presenter:

Paul Feldman, Ph.D., Chief Scientific Officer, Aktis Oncology

Title:

"Pioneering Aktis Oncology’s Miniprotein Radioconjugates"

Session:

Peptide Discovery to CMC

Location:

Hynes Convention Center, Boston, Mass.

Date:

Friday, May 17, 2024

Time:

11:15 a.m. ET